The study identified fast-tracked drugs in Europe and the U.S., and tracked their therapeutic value ratings to judge effectiveness at treating clinical conditions.
The study determined that 39 percent of the medications granted accelerated approval had therapeutic effectiveness, and 38 percent that were granted conditional market authorization had effectiveness.
Out of 146 medications, 122 were for cancer treatment.
In 2020, 53 percent of cancer-related drugs were fast tracked by the FDA.
In 1992, the FDA created an accelerated drug pathway for medications that could end serious diseases.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
